{"entity":{"id":"nct06934538","kind":"trial","name":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 1/2 trial of STC-1010 + IS regimen + SOC therapy in colorectal cancer, run by Brenus Pharma, now recruiting.","summary":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT06934538 by Brenus Pharma, with 90 participants planned, started 2025-06-17 and due to reach its primary completion in 2028-06. Interventions recorded: STC-1010 + IS regimen + SOC therapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06934538","url":"https://clinicaltrials.gov/study/NCT06934538"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06934538","phase":"1/2","setting":"Open Label, Multicenter, Dose-escalation and Cohort-expansion Phase I/IIA Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer (CRC) - BreAK CRC Trial (BreAK for Brenus Anti-cancer)","sponsor":"Brenus Pharma","enrolled":90,"outcomes":[]},"route":"/trials/nct06934538/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}]}}